Adagene (ADAG) Gets FDA Nod to Begin Solid Tumor Antibody Study

Published on November 30, 2021

The FDA grants Adagene (ADAG) a clearance to initiate clinical studies of its investigational candidate ADG116 in combination with pembrolizumab to treat advanced/metastatic solid tumors.

Continue reading on website
Other news

Why Should You Add ProAssurance (PRA) to Your Portfolio?

November 30, 2021
Riding on inorganic growth and cost-curbing measures, ProAssurance (PRA) holds the potential to reap benefits for investors.

What to Buy (and Skip) in December 2021

November 30, 2021
Wouldn’t it be convenient to wrap up the year with straightforward shopping advice? Alas, the retail landscape is still chaotic. So it’s hard to tell which products (if any) will…